Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets

Junhu Tai; Munsoo Han; Taehoon Kim

doi:10.3390/ijms23105523

Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets

Junhu Tai, Munsoo Han, Taehoon Kim

Department of Biomedical Sciences

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.

Original language	English
Article number	5523
Journal	International journal of molecular sciences
Volume	23
Issue number	10
DOIs	https://doi.org/10.3390/ijms23105523
Publication status	Published - 2022 May 1

Keywords

biologics
chronic rhinosinusitis
immunity
monoclonal antibody
therapeutic strategy

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Access to Document

10.3390/ijms23105523

Cite this

@article{66f7ef6c76574f27a2357a205ff2b261,

title = "Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets",

abstract = "Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.",

keywords = "biologics, chronic rhinosinusitis, immunity, monoclonal antibody, therapeutic strategy",

author = "Junhu Tai and Munsoo Han and Taehoon Kim",

note = "Funding Information: Funding: This research was supported by the Basic Science Research Program, National Research Foundation of Korea, funded by the Ministry of Science and Technology and the Ministry of Science, ICT & Future Planning (2017R1A2B2003575, NRF-2020R1A2C1006398), the Ministry of Science and ICT (2020R1C1C1012288), Korea, under the ICT Creative Consilience program (IITP-2022-2020-0-01819) supervised by the Institute for Information & Communications Technology Planning & Evaluation (IITP), the Korea Health Technology R&D Project (HI17C0387), Korea Health Industry Development Institute (KHIDI), and the Ministry of Health and Welfare. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = may,

day = "1",

doi = "10.3390/ijms23105523",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Therapeutic Strategies of Biologics in Chronic Rhinosinusitis

T2 - Current Options and Future Targets

AU - Tai, Junhu

AU - Han, Munsoo

AU - Kim, Taehoon

N1 - Funding Information: Funding: This research was supported by the Basic Science Research Program, National Research Foundation of Korea, funded by the Ministry of Science and Technology and the Ministry of Science, ICT & Future Planning (2017R1A2B2003575, NRF-2020R1A2C1006398), the Ministry of Science and ICT (2020R1C1C1012288), Korea, under the ICT Creative Consilience program (IITP-2022-2020-0-01819) supervised by the Institute for Information & Communications Technology Planning & Evaluation (IITP), the Korea Health Technology R&D Project (HI17C0387), Korea Health Industry Development Institute (KHIDI), and the Ministry of Health and Welfare. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/5/1

Y1 - 2022/5/1

N2 - Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.

AB - Chronic rhinosinusitis is a chronic inflammatory disease of the upper airways, for which treatment options include medical or surgical therapy. However, there are limitations to conservative treatment strategies, such as the relapse of nasal polyps. In this review, we discuss the rising role of biomolecular mechanisms associated with various biologics that have been approved or are undergoing clinical trials to treat chronic rhinosinusitis. We also highlight the potential molecular therapeutic targets for managing and treating chronic rhinosinusitis.

KW - biologics

KW - chronic rhinosinusitis

KW - immunity

KW - monoclonal antibody

KW - therapeutic strategy

UR - http://www.scopus.com/inward/record.url?scp=85129934263&partnerID=8YFLogxK

U2 - 10.3390/ijms23105523

DO - 10.3390/ijms23105523

M3 - Review article

C2 - 35628333

AN - SCOPUS:85129934263

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 10

M1 - 5523

ER -

Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this